SWEDY ORPHAN / S (OTCMKTS: SWTUY) Stock Market Quotation enhanced by Zacks Investment Research

ORPHAN / SWEDISH (OTCMKTS: SWTUY) Zacks Investment Research currently has a target price of $ 31.00 on the title

According to Zacks, "Swedish Orphan Biovitrum AB is a biopharmaceutical company that develops and manufactures drugs for patients with rare diseases. Kineret's main products include in the therapeutic area of ​​inflammation, Orfadin, Ammonaps and Ammonul within the genetic and metabolic therapeutics that are in the clinical trial phase. Orphan Biovitrum AB Secretary is based in Stockholm, Sweden .

Separately, ValuEngine updated SWEDISH ORPHAN / S shares of a conservation rating to a purchase note in a research report on Thursday, July 19.

Shares of SWEDISH ORPHAN / S fell $ 0.26 to $ 27.45 on Friday, according to Marketbeat. 3,595 shares of the company were exchanged for an average volume of 1,204 shares. SWEDISH ORPHAN / S has a minimum of $ 52.55 in 52 weeks and a high of $ 27.76 in 52 weeks. The company has a debt ratio of 0.23, a ratio of 1.46 and a ratio of 1.89. The company has a market capitalization of $ 7.37 billion, a P / E ratio of 54.90, a P / E / G ratio of 3.39 and a beta of 1.29.

SWEDISH ORPHAN / S (OTCMKTS: SWTUY) released its results on Thursday 26 April. The company reported earnings per share of $ 0.24 for the quarter, exceeding consensus analyst estimates of $ 0.17 per $ 0.07. SWEDISH ORPHAN / S had a net margin of 20.48% and a return on equity of 22.20%. The company achieved a turnover of $ 242.19 million for the quarter, compared with $ 218.76 million for analysts. Analysts predict that SWEDISH ORPHAN / S will show 1.08 EPS for the current fiscal year.

About ORPHELIN / SWEDISH

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures and markets pharmaceutical products in the therapeutic areas of Haemophilia, inflammation and genetics. and lysosomal diseases. The company offers Elocta to treat hemophilia A; and Alprolix to treat hemophilia B.

More reading: How Short Selling Works

Get a Free Copy of ZACK's Research Report on SWEDISH ORPHAN / S (SWTUY )

Zacks Investment Research research offers, visit Zacks.com

Receive news and ratings of SWEDISH ORPHAN / S Daily – Enter your email below to receive a concise summary of current news and insights analysts for ORPHEL SWEDISH / S and affiliates with MarketBeat.com's free daily newsletter.